Pyrrolidin-1-yl(quinoxalin-6-yl)methanone | 938160-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Pyrrolidin-1-yl(quinoxalin-6-yl)methanone
• CAS: 938160-11-3
• 化学式: C₁₃H₁₃N₃O
• mdl: MFCD10661936
• 分子量: 227.26
• InChiKey: ALJNIHFPBNQNRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  46.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel Quinoxaline Derivatives and Their Medical Use
  申请人：Peters Dan

  公开号：US20090286797A1

  公开（公告）日：2009-11-19

  This invention relates to novel quinoxaline derivatives having medical utility, to use of the quinoxaline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinoxaline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to positive modulation of AMPA receptor mediated synaptic responses.

  本发明涉及具有医疗用途的新型喹喔啉衍生物，涉及使用本发明的喹喔啉衍生物制造药物，涉及包含本发明的喹喔啉衍生物的制药组合物以及涉及治疗与正向调节AMPA受体介导的突触反应有关的主体的疾病、疾病或病症的方法。
• NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE
  申请人：NeuroSearch A/S

  公开号：EP1960373A2

  公开（公告）日：2008-08-27
• [EN] NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] NOUVEAUX DÉRIVÉS DE QUINOXALINE ET LEUR UTILISATION MÉDICALE
  申请人：NEUROSEARCH AS

  公开号：WO2007060144A2

  公开（公告）日：2007-05-31

  [EN] This invention relates to novel quinoxaline derivatives having medical utility, to use of the quinoxaline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinoxaline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to positive modulation of AMPA receptor mediated synaptic responses.
  [FR] La présente invention concerne de nouveaux dérivés de quinoxaline pouvant être employés en médecine, l'utilisation des dérivés de quinoxaline selon l'invention dans la fabrication d'un médicament, des préparations pharmaceutiques comprenant les dérivés de quinoxaline selon l'invention, et des méthodes de traitement d'un trouble, d'une maladie ou d'un état pathologique chez un sujet, ledit trouble, ladite maladie ou ledit état pathologique réagissant à une modulation positive des réponses synaptiques faisant intervenir le récepteur AMPA.